Alnylam Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its treatment vutrisiran, aiming to compete with therapies from BridgeBio and Pfizer. The drug is approved for patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition, with the goal of reducing cardiovascular-related deaths and hospitalizations. This indication was widely anticipated by investors. Additionally, vutrisiran has been cleared to decrease urgent heart failure visits.
Source: https://www.statnews.com/2025/03/20/alnylam-vutrisiran-fda-approval-attr-cm-bridgebio-pfizer